Posted BY: | NwoReport
Eli Lilly and Co. said it will cut prices of its most commonly prescribed insulins up to 70% and expand a program that limits out-of-pocket monthly costs for some consumers.
The Indianapolis drugmaker’s price cuts and discounts for insulin come as federal and state lawmakers and patient advocates pressure drug companies and health insurers to improve affordability for the lifesaving medication used by millions of Americans.
“The aggressive price cuts we’re announcing today should make a real difference for Americans with diabetes,” said Lilly Chair and CEO David Ricks.
Trending: WHO moves forward with plans to target “misinformation” and “disinformation” under international law
Eli Lilly discounts Humalog and Humulin insulin
The drugmaker will cut list prices by 70% for the fast-acting injectable Humalog, which is the company’s most commonly prescribed insulin. Lilly also will discount an older fast-acting drug, Humulin.
